Pathologic
Assessment of
Invasion in TUR
Specimens

A. Lopez-Beltran

T1 (cT1)

Prognostic factors for progression/invasive disease Ta,T1,CIS- NMIBC :TNM 2017

- ESSENTIAL:
- Grade
- T stage
- CIS
- Number of lesions
- Previous recurrences
- ADDITIONAL
- · Recurrence at 3 month check
- Tumor size>> 3 cm


Prognostic factors metastasis risk/Survival MIBC T2-4No-1


:TNM 2017


- ESSENTIAL:
- T category
- N category
- ADDITIONAL
- Grade
- Histological type
- IVI
- Concomitant CIS
- Tumor size
- Hydronephrosis


Background


- T1 assessment and pitfalls
- T1 substaging-Proposals
- T2 assessment and pitfalls
- AJCC/TNM 2017




























Important pathologic problem: Reproducibility in pT1


Reproducibility of lamina propria invasion


(reviewed by Lopez-Beltran and Cheng, 2003

- 61% agreement; 10% NO consensus after 4 rounds
- 15% of pT1 down-staged as pTa
- 22% of pT2 down-staged to pT1 or pTa
- 80% agreement; 88% after a 2nd round
- 35% pT1 to pTa; 3% to pT2-T3
- 2nd TURBT found: 2-28% pT1 to be at least pT2
- pT1 (experts) study: (Histopathology 2013)
- Full agreement (44%)
- Majority consensus (72%)
- Kappa ~ 50%













T1 Substaging


Year	Author	Staging system	Number of cases	Progression (%)	Survival (%
1990	Younes et al. [6]	Tla (lamina propria) Tlb (into MM) Tlc (across MM)	15 3 14	NA	75 11
1994	Hasui et al. [8]	Tla (Younes Tla) Tlb (Younes Tlb and c)	60 ^a 28 ^a	6.7 53.5	95 82
1995	Angulo et al. [21]	Tla (Younes Tla and b) Tlb (Younes Tlc)	50 ^a 49 ^a	NA NA	86 52
1997	Holmäng et al. [9]	Tla (Younes Tla) Tlb (Younes Tlb and c)	26 38	36 58	58 42
1998	Smits et al. [10]	Tla Tlb Tlc	119 total ^a	6 33 55	NA NA NA
1998	Hermann et al. [22]	Tla Tlb Tlc	31 ^b 60 ^b 52 ^b	NA NA NA	79 70 57
1999	Cheng et al. [11]	T1 above MM T1 into or below MM	23 ^a 21 ^a	11 32	NA NA
2000	Kondylis et al. [7]	T1a into MM T1b beyond MM	32 ^b 17 ^b	22 29	NA NA
2001	Bemardini et al. [20]	T1a (Younes T1a) T1b (Younes T1b and c)	54 ^a 40 ^a	e	NA NA
2003	Trias et al. [12]	Tla (Younes Tla) Tlb (Younes Tlb and c)	11 13	9 30.7	NA NA












Histopathology 2011, 59, 722-732. DOI: 10.1111/j.1365-2559.2011.03989.x

Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer—evaluation of a large hospital-based single-centre series

Simone Bertz, Stefan Denzinger, Wolfgang Otto, Wolf F Wieland, Robert Stoehr, Ferdinand Hofstaedter & Arndt Hartmann

Methods and results: Specimens of 309 patients with pT1 urothelial carcinoma were re-evaluated histologically, including size of infiltrating tumour area estimated as equal to or smaller than one high-power field (HPF) or larger than one HPF, and tumour infiltration in relation to the muscularis mucosae (pT1a/b). Results were correlated with clinical follow-



Histopathology

Histogethology 2017, 71, 406-414. DOI: 10.1111/hts.13247

Stalk versus base invasion in pT1 papillary cancers of the bladder. improved substaging system predicting the risk of progression

Margaret Lawless, ¹ Roman Gulati² (b) & Maria Tretiakova ¹ (c)

¹ Department of Pathology, University of Washington School of Medicine, Soutile, WA, USA, and ²Fred Hutchison
Canner Research Center, South, WA, USA


Alms: Pathological stage PTI blader cancers constitute a clinically heterogeneous group. However, current staging guidelines for superficially invasive cancers do not acknowledge the variability in type and extent of lamina propria invasion in papillary unothelial carcinomas (PUC), and historically proposed substaging systems showed either high interobserver surfation or limited value in predicting patient outcomes. The aim of this study was to reappraise pTI PIC substaging, with the objective of identifying a novel scheme that is reproducible and prognostically meaningful.

Methods and results: pT1 PUCs diagnosed during 1999–2015 were retrospectively reviewed and characterized as focal invasion onlined to the papillary stalk, focal invasion of the tumour base, or extensive invasion of the tumour base. Cases with concurrent flat carcinoma in situ, angiolymphatic invasion, absent muscularis propria or clinically advanced

disease were excluded. We calculated cumulative incidence rates of recurrence, progression and death by tumour subtype, and evaluated differential risks by tumour subtype, and evaluated differential risks by tumour subtype, and extent of invasion. Among 62 patients statisfying the inclusion criteria, 22 of 29 patients with base-extensive invasion progressed, whereas four of 13 with base-focal and none of 20 with stalls-only invasion progressed. There was strong evidence that base-extensive patients had a higher risk of progression and death resulting from bladder cancer than base-focal or stalk-only patients (P < 0.0001). However, tumour subtype was not significantly associated with risk of recurrence (P = 0.21).

Conclusions: We propose an innovative substaging approach for reporting the site and extent of lamina propria invasion in patients with pT1 PUC, allowing patient stratification for risk of progression.

Recent proposals for T1 substaging



Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens

Comparison and Ranking of T1 Quantification Approaches to Predictabstract: Urothelial carcinoma of the bladder invasive into lamina propria on biopsy or transurethral resection of bladder tumor, biopsy or transurethral resection of bladder tumor, and the propria on biopsy or transurethral resection of bladder tumor, and the propria of the propria of


Mariah Z. Leivo, MD,* Debashis Sahoo, PhD,† Zachary Hamilton, MD,‡ Leili Mirsadraei, MD,
Ahmed Shabaik, MD,* John K. Parsons, MD, PhD,‡ Andrew K. Kader, MD,‡ Ithaar Derweesh, MD,
Christopher Kane, MD,‡ and Donna E. Hansel, MD, PhD*‡


subset of patients. Prior studies have proposed histopathologic metrics to predict progression, although methods vary widely and it is unclear which method is most robust. This poses a challenge since recent World Health Organization and American Joint Commission


Recent proposals for T1 substaging


propria on biopsy or transurethral resection of bladder tumor, termed "T1" disease, progresses to muscularis propria invasion in a subset of patients. Prior studies have proposed histopathologic metrics to predict progression, although methods vary widely and it recent World Health Organization and American Joint Commission on Cancer editions encourage some attempt to substratify T1 disease. To address this critical problem, we analyzed T1 specimens to test which T1 quantification method is best to predict progression and to then establish the optimal cut-off. Progression was analyzed for all patients or for patients with definitive muscularis propria only. Multivariate analysis and outcomes modeling controlled for additional histopathologic features. Our results suggest that aggregate linear length of invasive carcinoma (ALLICA) measured by optical micrometer is far superior to other methods ($P = 3.067 \times 10^{-1}$ and could be applied to 100% of specimens. ALLICA retained significance in multivariate analysis and eliminated contribution of other histopathologic features to progression. The best cut-off for ALLICA using a 30% false-positive threshold was 2.3 mm and using a 10% false-positive threshold at 25 mm, although the latter severely limited patients who could achieve this threshold. After comparison of all proposed methods of T1 quantification, we recommend the adoption of the ALLICA measurement and a cut-off of ≥ 2.3 mm as the best predictor of progression, acknowledging that additional nonhistopathologic methods may be required to increase broad applicability and further reduce the false-positive threshold.

Another important issue in pT1 is the level of invasion Microinvasion vs. established invasion











PATHOLOGIC ISSUES IN DIAGNOSIS OF LAMINA PROPRIA MICROINVASION How we do identify invasion?

- HOW: General Features
- Histologic grade
- Stroma-epithelial interface (basement membrane)
- Invading epithelium
- Stromal response
- WHERE: Bladder Tumors with MICROINVASION
- CIS with microinvasion
- Papillary urothelial carcinoma with microinvasion
- Papillary urothelial carcinoma with invasion into stalk
- Well-established invasion into underlying lamina propria
- Urothelial carcinoma with endophytic/broad front growth pattern




Invasive Low-grade Papillary Urothelial Carcinoma: A Clinicopathologic Analysis of 41 Cases

Adam D. Toll, MD* and Jonathan I. Epstein, MD*†;




Lamina propria invasion Main Issues to identify


- Invading epithelium
 - Irregularly shaped nests
 - Single cell infiltration
 - Irregular or absent basement membrane
 - Tentacular finger-like processes
 - Invasive component with higher nuclear grade or more cytoplasm: paradoxical differentiation
 - Vascular invasion





Lamina propria microinvasion Main Issues to identify


- Stromal response
 - Desmoplasia
 - Retraction artifact
 - Inflammation
 - Myxoid stroma
 - Pseudosarcomatous stroma
 - Absent stroma response















There are always difficult cases>> inform the urologisti

Microinvasion Examples



















Invasive Growth Patterns of Cancer

- The diagnosis of invasion should be made when there are:
- Irregularities of the contours of the neoplastic nests
- Jagged edges
- Desmoplastic or inflammatory stroma surrounding these nests.

Invasive Bladder Cancer Stage pT2 at least





Bladder Cancer Staging

AJCC/TNM 2016. Category T

To... No evidence of primary tumor

Tis... Urothelial Carcinoma "In Situ" (Flat Tumor)

Ta... Papillary tumor without invasion

T1... Subepithelial connective tissue invasion (invades lamina propria)

T2... Muscularis propia invasion

a.- Superficial invasion (inner half)

b.- Deep (outer half)

T3... Perivesical fat tissue invasion

a.- Microscopically


b.- Macroscopically

T4...Extravesical invasions

a.-Prostatic stroma, uterus, vagina

b.-Pelvic wall, abdominal wall

75%




Invasive urothelial carcinoma Depth of invasion

- pT system of staging has an excellent correlation with prognosis
- 5-year survival

_	pT1	
	-T2	

40% − pT2 pT3-pT4 20%










Fig. 1. Cumulative incidence of bladder cancer death by pathologic stage










Defining invasion of muscularis propria?

- Confusing terms that should be avoided:
- Superficial muscle invasion
- Deep muscle invasion
- Muscle invasion NOS
- Distinction between muscularis mucosae and muscularis propria is critical>>therapy
- Numerous blood vessels admixed with small bundles of smooth mucle>> MM
- Dense bundles of smooth muscle>> MP


Biblioteca Universitaria de CórdobaBiblioteca Universitaria de Córdoba





Are there situations in which it is difficult to define MP?

- Difficult cases?
- Inform the urologist?
- In selected cases (rare)>>diagnosis of undeterminate for type of mucle>>R-Resection is mandatory
- Do not atempt to substage MP invasion (Turb)
- Presence/absence of MP should be included always in the final report
 >>> feedback to the urologist
- Cauthery artefact>>difficult to differentiate in some cases MM vs. MP
 - IHC with anti-smooth muscle actin/desmin/smoothelin/vimentin>>helpful in selected cases

Difficult cases?
Example







pT1 Categorization

Several experts have recommended substaging of pT1 disease, and numerous subcategories have been proposed. Although not formally endorsed in this staging system, pT1 categorization appears to have prognostic value, with early invasion ("microinvasive disease") into the lamina propria showing better outcomes than more advanced pT1 disease. The method of pT1 substaging has not been optimized, but microinvasive disease has been defined by different groups as invasive tumor of <1 high power field in content, greatest invasive tumor diameter of 1 mm, or invasive tumor above the muscularis mucosae extending to a depth of 2 mm or less. An attempt to categorize pT1 disease is strongly recommended using one of the above methods.^{24–26}AJCC Level of Evidence: II

Perivesical lymph node involvement is classified as N1

M1 is subdivided into M1a and M1b.
M1a refers to a non-regional lymph node only.
M1b refers to non-lymph-node distant metastases.

Stage III is subdivided into IIIA and IIIB. Stage IV is subdivided into IVA and IVB.

Definition of Primary Tumor (T)				
T Category	T Criteria			
TX	Primary tumor cannot be assessed			
ТО	No evidence of primary tumor			
Ta	Non-invasive papillary carcinoma			
Tis	Urothelial carcinoma in situ: "flat tumor"			
TI	Tumor invades lamina propria (subepithelial connective tissue)			
T2	Tumor invades muscularis propria			
pT2a	Tumor invades superficial muscularis propria (inner half)			
pT2b	Tumor invades deep muscularis propria (outer half)			
T3	Tumor invades perivesical soft tissue			
рТ3а	Microscopically			
pT3b	Macroscopically (extravesical mass)			
T4	Extravesical tumor directly invades any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall			
T4a	Extravesical tumor invades directly into prostatic stroma, uterus, vagina			
T4b	Extravesical tumor invades pelvic wall, abdominal wal			

Take-Home Messages

- There is a need to define T1 sub-staging with criteria and methods to be applied
- When detrusor muscle is positive sign out as stage T2 at least
- When not clear if positive muscle is MM or MP talk to urologist
- A R-TUR will solve the problem in most cases
- IHC has potential value in selected cases.
- Follow AJCC 2017 in practice



THANKS